Research programme: phospholipid drug conjugates - Cellectar Biosciences/LigaChem Biosciences
Alternative Names: Small molecule phospholipid drug conjugates - Cellectar Biosciences/LigaChem BiosciencesLatest Information Update: 07 Aug 2024
At a glance
- Originator Cellectar Biosciences; LegoChem Biosciences
- Developer Cellectar Biosciences; LigaChem Biosciences
- Class Antineoplastics; Drug conjugates; Phospholipid ethers; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Aug 2024 Preclinical trials in Solid tumours in South Korea, USA (Parenteral) prior to August 2024 (Cellectar Biosciences pipeline, August 2024)
- 12 Jul 2021 Cellectar Biosciences and LegoChem Biosciences signs development and commercialisaion agreement for phospholipid drug conjugates
- 12 Jul 2021 Early research in Solid tumours in South Korea (Parenteral)